LBA23 Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)
Year: 2023
Type: conference-abstract
Source: Annals of Oncology
Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Dolnośląskie Centrum Onkologii, Yonsei Cancer Hospital, St. Vincent's University Hospital, Seoul National University, Seoul National University Hospital, LMU Klinikum, Ludwig-Maximilians-Universität München, Baylor University Medical Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Latin American Cooperative Oncology Group (LACOG), Orlando Health, Translational Research in Oncology, Novartis (United States), Novartis (Ireland)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, Genomic Health, Merck KGaA, Taiho Pharmaceutical, Exelixis, Les Laboratories Pierre Fabre, Ipsen Biopharmaceuticals, Radius Health, Mylan, Mersana Therapeutics, Carrick Therapeutics, Syndax Pharmaceuticals, G1 Therapeutics, Seagen, Eisai, Daewoong Pharmaceutical Company, Astellas Pharma, Ipsen, LEO Pharma, Genentech, Samsung, Daiichi Sankyo Europe
OpenAlex ID: W4387809689